Bio-Rad Laboratories, Inc.

BIO

NYSE; business equipment; SIC 3826, Laboratory Analytical Instruments; CIK 0000012208

D

fourth fifth of 469 graded peers in business equipment

rank 359 of 469; percentile 76.5; sampling error 2.3 points; lower is stronger

A B C D E

D, the sloth



Scoreboard	
Profitability	D percentile 72.1
Solvency	B/C percentile 41.4
Growth and financing	D percentile 65.9
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $10.6B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: dilution, distress
Inputs computable	12 of 13
Graded from	filings received through Feb 13, 2026 282 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026
Last close	$359.05 2026-11-20; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 13, 2026

Bio-Rad Laboratories, Inc. (referred to in this report as "Bio-Rad," "we," "us," "the Company," and "our") is a multinational life science and clinical diagnostics company that develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables. We have direct operations in over 36 countries outside the United States through subsidiaries focused on sales, customer service, and product distribution. In certain locations outside and within these countries, our sales efforts are supplemented by distributors and agents. Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics. Both segments operate worldwide.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 72.1						
Gross profitability	12.7%	29.4%		79.7	513	2025-12-31
Return on invested capital	0.5%	11.2%		83.6	123	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	2.3%	(7.4%)	89.9	566	2025-12-31
Gross margin stability, five years	1.6 pts	2.3 pts	35.1	406	2025-12-31
Solvency, sleeve percentile 41.4					
Altman Z double-prime	6.54	2.18	16.7	517	2025-12-31
Net debt to EBITDA	3.20x	1.11x	76.6	138	2025-12-31
Interest coverage	0.96x	4.90x	58.2	80	2025-12-31
Current ratio	5.62x	1.98x	14.0	600	2025-12-31
Growth and financing, sleeve percentile 65.9					
Revenue growth, three-year compound	(2.7%)	6.6%	75.1	503	2025-12-31
Free cash flow growth, three-year compound	66.2%	17.4%	14.3	253	2025-12-31
Reinvestment rate	(502.6%)	14.3%	93.4	213	2025-12-31
Asset growth, three years	(7.8%)	5.0%	80.7	519	2025-12-31
Net share issuance, one year	not computable	0.5%			

firm-wide XBRL shares cannot be assigned to one ticker class

Among 469 peers

business equipment; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
354	L3Harris Technologies, Inc. (LHX)	75.4	D	
355	Beam Global (BEEM)	75.6	D	short runway, late filer
356	Bumble Inc. (BMBL)	75.9	D	
357	Vishay Intertechnology Inc. (VSH)	76.1	D	
358	EverCommerce Inc. (EVCM)	76.3	D	
359	Bio-Rad Laboratories, Inc. (BIO)	76.5	D	
360	Automatic Data Processing Inc. (ADP)	76.7	D	fortress balance sheet
361	Gen Digital Inc. (GEN)	76.9	D	
362	AmpliTech Group, Inc. (AMPG)	77.1	D	fortress balance sheet
363	Harvard Bioscience Inc. (HBIO)	77.4	D	
364	Airgain Inc. (AIRG)	77.6	D	

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	18.2%	(2.2%)	64
Distance from 52-week high	(8.1%)	(41.7%)	92
EBIT to enterprise value	not computable	2.0%	
Free cash flow yield	not computable	3.1%	
Book value to price	not computable	0.31	
Sales to price	not computable	0.35	
Composite equity issuance, five years	not computable	4.3%	
Relative strength against the sector, log excess return	(0.10)	(0.29)	64
Twelve-month failure probability, CHS model	not computable	0.05%	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$465.3M
Operating cash flow, four quarters	$468.1M
Months of runway	not finite
Days since last periodic filing	18 (10-Q received Nov 4, 2026)
Median daily dollar volume, 63 sessions	$92.7M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$1.3B	2025-12-31	2026-02-13	10-K	26-000010
2	assets	us-gaap:Assets	$10.6B	2025-12-31	2026-02-13	10-K	26-000010
3	operating income	us-gaap:OperatingIncomeLoss	$47.2M	2025-12-31	2026-02-13	10-K	26-000010
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$995.5M	2025-12-31	2026-02-13	10-K	26-000010
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$235.6M	2025-12-31	2026-02-13	10-K	26-000010
6	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$1.2B	2025-12-31	2026-02-13	10-K	26-000010
7	book equity	us-gaap:StockholdersEquity	$7.5B	2025-12-31	2026-02-13	10-K	26-000010
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$529.8M	2025-12-31	2026-02-13	10-K	26-000010
9	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$1.2B	2024-12-31	2025-02-14	10-K	25-000007
10	book equity	us-gaap:StockholdersEquity	$6.6B	2024-12-31	2026-02-13	10-K	26-000010
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$488.1M	2024-12-31	2026-02-13	10-K	26-000010
12	net income	us-gaap:NetIncomeLoss	$759.9M	2025-12-31	2026-02-13	10-K	26-000010
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$532.2M	2025-12-31	2026-02-13	10-K	26-000010
14	assets	us-gaap:Assets	$9.4B	2024-12-31	2026-02-13	10-K	26-000010
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.6B	2025-12-31	2026-02-13	10-K	26-000010
16	gross profit	us-gaap:GrossProfit	$1.4B	2024-12-31	2026-02-13	10-K	26-000010
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.6B	2024-12-31	2026-02-13	10-K	26-000010
18	gross profit	us-gaap:GrossProfit	$1.4B	2023-12-31	2026-02-13	10-K	26-000010
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.7B	2023-12-31	2026-02-13	10-K	26-000010
20	gross profit	us-gaap:GrossProfit	$1.6B	2022-12-31	2025-02-14	10-K	25-000007
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.8B	2022-12-31	2025-02-14	10-K	25-000007
22	gross profit	us-gaap:GrossProfit	$1.6B	2021-12-31	2024-02-16	10-K	24-000013
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.9B	2021-12-31	2024-02-16	10-K	24-000013
24	current assets	us-gaap:AssetsCurrent	$2.9B	2025-12-31	2026-02-13	10-K	26-000010
25	current liabilities	us-gaap:LiabilitiesCurrent	$517.0M	2025-12-31	2026-02-13	10-K	26-000010
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$8.2B	2025-12-31	2026-02-13	10-K	26-000010
27	liabilities	us-gaap:Liabilities	$3.1B	2025-12-31	2026-02-13	10-K	26-000010
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$165.4M	2025-12-31	2026-02-13	10-K	26-000010
29	interest expense	us-gaap:InterestExpense	$49.0M	2025-12-31	2026-02-13	10-K	26-000010
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$157.6M	2025-12-31	2026-02-13	10-K	26-000010
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$455.2M	2024-12-31	2026-02-13	10-K	26-000010

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$165.6M	2024-12-31	2026-02-13	10-K	26-000010
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$374.9M	2023-12-31	2026-02-13	10-K	26-000010
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$156.7M	2023-12-31	2026-02-13	10-K	26-000010
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$194.4M	2022-12-31	2025-02-14	10-K	25-000007
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$112.8M	2022-12-31	2025-02-14	10-K	25-000007
37	current assets	us-gaap:AssetsCurrent	$3.0B	2024-12-31	2026-02-13	10-K	26-000010
38	current liabilities	us-gaap:LiabilitiesCurrent	$467.8M	2024-12-31	2026-02-13	10-K	26-000010
39	assets	us-gaap:Assets	$12.3B	2023-12-31	2025-02-14	10-K	25-000007
40	assets	us-gaap:Assets	$13.5B	2022-12-31	2024-02-16	10-K	24-000013

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.